Cite
HARVARD Citation
Arnott, C. et al. (2021). The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes, obesity & metabolism. 23 (7), pp. 1652-1659. [Online].